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Abstract: European and American guidelines recommend surveillance for hepatocellular carcinoma
(HCC) by performing ultrasonography on a six-month basis on an at risk population, defined by
presence of cirrhosis. HCC, due to non-alcoholic steatohepatitis (NASH), is rising. Patients with
NASH have a high risk of developing HCC and, therefore, have to be enrolled in a screening program.
One of the challenges with NASH-induced HCC is that half of the cases arise in non-cirrhotic patients.
There is a need to identify those patients in order to screen them for HCC. The obesity of these patients
is another challenge, it makes ultrasound screening more difficult. Other radiological methods, such
as computer tomography (CT) scans or magnetic resonance imaging (MRI), are available, but the
surveillance program would no longer be cost-effective. There is a need to prospectively acquire
information on cohorts of patients with NASH in order to improve the tools we have to diagnose
early tumors in these patients.
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1. Introduction
In oncology, surveillance means enrollment in a program where a screening test is regularly
applied to an at risk population. The goal is to identify cancers at an early stage, which can be
better treated and—other as consequence—improves the outcome of the patients. For hepatocellular
carcinoma (HCC), American and European guidelines have a clear position regarding surveillance [1,2].
The screening test is ultrasonography of the liver, applied on a six-month basis to a population at
risk, defined by the presence of cirrhosis. In areas where the hepatitis B virus (HBV) is endemic
and where the carcinogen aflatoxin can be found, the recommendations are to screen HBV positive
patients, starting at defined ages, independent of the presence of cirrhosis. Two randomized controlled
trials (RCT) performed in Asia aimed to assess the outcomes of a surveillance program. The first
compared screening, by measuring alphafetoprotein (AFP) and performing ultrasonography against
no screening in HBV-infected Chinese patients and found a reduction of mortality by 37% in the
screened group, mostly because more patients could undergo surgical resection [3]. However, this
study has some limitations, as adherence to the screening program was suboptimal (58%) and the
study does not give any information about the level of fibrosis in the liver. The second study was
performed in HBV-infected men with a six-month interval AFP screening. Although they found a
significantly higher proportion of early HCC in the surveillance group (29.6% against 6.0%), there
was no difference in the five-year survival between groups [4]. This study also had a low compliance
(below 50%) and only used AFP. The use of AFP as a screening test is controversial, since many HCCs
will never produce AFP and it can be elevated in patients with cirrhosis without tumor. These two
studies are far from perfect, but the field has evolved so much that there will very likely be no better
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RCT to support regular screening in a population at risk for HCC. Nonetheless, a recent meta-analysis,
based on 47 retrospective and prospective studies, showed that HCC surveillance is associated with
improved early tumor detection, receipt of curative therapy, and overall survival in patients with
cirrhosis [5].
2. The Incidence of NASH-Induced HCC Is Growing
The number of patients affected by HCC is increasing [6], probably for several reasons: Better
surveillance of patients at risk, the aging cohort of hepatitis C (HCV)-infected patients, and the
increasing importance of non-alcoholic steatohepatitis (NASH) in the landscape of liver diseases [7].
NASH can progress to cirrhosis and to HCC [8–10] and, therefore, patients with cirrhosis due to NASH
have to be enrolled in a surveillance program for HCC. One has to recognize that histological diagnosis
of a NASH is difficult at the stage of cirrhosis, since characteristic features disappear at this stage. The
majority of cryptogenic cirrhosis is actually burned out NASH [11,12].
Patients with NASH are at particular risk to develop HCC. They have clinical abnormalities
linked to this type of tumor. Obesity in young adults (mid-20s to mid-40s) has been identified as
a risk factor (OR = 2.6) for HCC in a case-control study in the United States [13]. Even obesity in
childhood (between 7 and 13 years old) has been reported to be associated with HCC later in life
in a retrospective cohort of 285,884 Danish boys and girls [14]. Obesity increases the risk for many
cancers, but the odd ratio is particularly high for HCC. In a prospective study comparing relative risk
for various cancers in men with normal weight against men with a BMI of >35, liver cancer had the
highest relative risk (RR = 4.25) [15]. In a cohort of 30,201 patients who underwent liver transplantation
from the United Network of Organ Sharing (UNOS), obesity was independently predictive for HCC
in cryptogenic cirrhosis (OR = 11.1) [16]. Diabetes mellitus has been, in many studies, associated
with HCC in retrospective, as well as in prospective, studies. In the United States, a study showed
an increased risk for HCC (RR = 2.13) by following 216,831 patients diagnosed with diabetes [17].
An analysis of a retrospective cohort with 153,852 Swedish patients with diabetes showed a four-fold
increased risk for primary liver cancer during a 1–24 year follow-up [18]. A prospective study in Asia
showed that obesity and diabetes had synergistic effects in hepatitis-infected patients, with a 100-fold
increased risk for HCC [19]. Interestingly, due to the high prevalence of diabetes and obesity in the
United States, even if the OR for HCC is far less for diabetes and/or obesity (OR = 2.47) than for other
risk factors, such as HCV (OR = 39.89), those factors have the greatest population attributable fraction.
This means that the elimination of diabetes and/or obesity could reduce the incidence of HCC, more
than the elimination of any other factor [20]. With that objective in mind, studies showed that the risk
factors for HCC, represented by diabetes mellitus, could be mitigated. Firstly, antidiabetic drugs like
metformin could lower the risk of developing HCC. A meta-analysis based on three cohort studies
and four case-control studies showed a significantly-reduced risk of HCC in diabetic patients using
metformin [21]. Secondly, lifestyle modifications could also prevent the development of HCC, as has
been shown in animals [22].
3. Identifying and Screening Patients with NASH
It appears that in the last few years, HCC, in the context of NASH, arises in half of the cases before
cirrhosis. In a pathological analysis of 31 resected HCC patients in France with metabolic syndrome
as the only risk factor, most of the patients had a no significant fibrosis [23]. In Japan, pathological
analysis of 87 NASH patients with HCC revealed that only 51% of the patients had liver cirrhosis,
with a lower prevalence among men compared with women (39% versus 70%) [24]. In a retrospective
analysis of 120 HCC patients with non-alcoholic fatty liver disease (NAFLD) in the United States, 58.3%
of them had cirrhosis [25]. Patients with NASH-induced HCC often present with large tumors and
have a worse prognosis than those with other etiologies. In a retrospective analysis of the Surveillance,
Epidemiology and End Results (SEER)-Medicare database, 50% of viral-hepatitis-infected patients
with HCC died after one year, whereas 61% of the NAFLD patients with HCC died after one year [26].
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This can be due to the fact that they are older, that they often have comorbidities [27], and also that
these patients have not been involved or enrolled in a surveillance program. Indeed, since about half of
patients with NASH develop HCC before cirrhosis, these patients will not be enrolled in a surveillance
program. A retrospective analysis of a cohort with 1500 HCC patients from Veterans Administration
(VA) hospitals showed that patients with NAFLD-HCC underwent less-frequent surveillance (43.3%)
in the three years before HCC diagnosis than patients with alcohol- (59.8%) or HCV-induced (86.7%)
HCC [25]. This raises a very important challenge for research in the next years. We need to identify
patients with NASH at risk of developing HCC, and those who are not, to respectively enroll them
in a surveillance program or not. We need to discover these parameters, which can be circulating
biomarkers, which can be genetic markers, or a combination of both. The variation in the PNPLA3 gene
has been associated with steatohepatitis, with fibrosis, cirrhosis, and also HCC. In a study comparing
genotype frequencies between NAFLD-HCC cases and NAFLD-controls, the carriage of the PNPLA3
rs738409 C > G polymorphism increased the risk for HCC [28]. This single nucleotide polymorphism
(SNP) can be one tool in helping to stratify patients. This tool is not perfect, and it needs to be
supplemented with other parameters.
Another challenge of surveillance in patients with NASH is due to the fact that obesity
compromises the completeness of an ultrasound examination of the liver. In these patients, it is
difficult to examine all the segments of the liver. An Italian study showed that a BMI > 25 was
significantly associated with ultrasound surveillance failure [29]. For this reason, it is not rare to have
to perform CT scans or MRIs to get better images of the liver in these patients. This complicates
surveillance and also increases costs. It has been shown that surveillance programs by application of
regular sonographies in patients at risk for HCC are cost effective. However, this would no longer be
the case if MRIs or CT scans have to be performed [30]. A study based on cirrhotic patients suggested
that AFP has a better sensitivity and specificity in NAFLD patients than in HCV-patients, with a
sensitivity of 89.7% and a specificity of 85.1% at a cut-off value of 20 ng/mL in NAFLD patients [31].
According to the low number of NAFLD patients with HCC in that study (n = 39), this result has to
be assessed in a bigger sample, which also contains non-cirrhotic patients. Nonetheless, also here,
identification of biomarkers with a better accuracy than alpha-fetoprotein is urgently needed.
4. Conclusions
The challenge for physicians engaged in the treatment of patients with NASH will be in the
coming years, to earlier diagnose HCC in patients at particular risk. We need to improve the tools
that we have to do that. In order to achieve this goal, we need to prospectively acquire information
on cohorts of patients with NASH. This is the only way to propose an earlier diagnosis for better
treatment and longer survival in these patients.
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